Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Congress Needs To Review “Authorized” Generics, Hatch And Waxman Agree

Executive Summary

Congress will likely have to look at the issue of "authorized" generics, Sen. Orrin Hatch (R-Utah) and Rep. Henry Waxman (D-Calif.) said during an Oct. 6 Drug & Device Dialogue audio conference sponsored by FDC Reports and Polidais LLC

You may also be interested in...



FTC Should Study Competitive Impact Of “Authorized” Generics, Senators Say

A bipartisan group of senators is asking the Federal Trade Commission to study the competitive impact of "authorized" generics

FTC Should Study Competitive Impact Of “Authorized” Generics, Senators Say

A bipartisan group of senators is asking the Federal Trade Commission to study the competitive impact of "authorized" generics

“Authorized” Generics Will Be Subject To “Best Price” Calculations – CMS

The Centers for Medicare & Medicaid Services is indicating that it will consider "authorized" generics to be brand drugs for the purposes of best price reporting

Related Content

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel